Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...
Genmab AS (GMAB) posts broad-based 22% revenue growth, maintains full-year guidance toward the upper end, and touts three positive Phase 3 readouts with multibillion-dollar peak sales potential. Related Stocks: GMAB ,